

NICE Technology Appraisals - Time to Implementation Report - 3rd August 2015

Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
26 Sep 2012	TA264	Stroke (acute, ischaemic) - alteplase - ***Review of TA122***	<p>Alteplase is recommended within its marketing authorisation for treating acute ischaemic stroke in adults if:</p> <ul style="list-style-type: none"> - treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and - intracranial haemorrhage has been excluded by 	09/11/2012	44
24 Oct 2012	TA265	Bone metastases from solid tumours - denosumab	<p>1.1 Denosumab is recommended as an option for preventing skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than prostate if:</p> <ul style="list-style-type: none"> - bisphosphonates would otherwise be prescribed and - the manufacturer provides denosumab with the discount agreed in the patient access scheme. <p>1.2 Denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer.</p>	04/01/2013	72
28 Nov 2012	TA266	Cystic fibrosis - mannitol dry powder for inhalation	NICE recommends mannitol dry powder for inhalation as a possible treatment for some adults with cystic fibrosis.	04/01/2013	37
28 Nov 2012	TA267	Chronic heart failure - ivabradine	NICE recommends ivabradine as a possible treatment for some people with chronic heart failure.	04/01/2013	37

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
12 Dec 2012	TA270	Leukaemia (acute myeloid) - decitabine (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of decitabine for acute myeloid leukaemia because no evidence submission was received from the manufacturer of the technology.	04/01/2013	23
12 Dec 2012	TA269	Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	Vemurafenib is recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.	04/01/2013	23
12 Dec 2012	TA268	Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.	04/01/2013	23
23 Jan 2013	TA273	Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)	NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the	01/03/2013	37
23 Jan 2013	TA272	Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine	NICE does not recommend vinflunine for people with advanced or metastatic transitional cell cancer of the urothelial tract that has been treated previously with platinum-containing cancer drugs. NICE conclude that vinflunine does not provide enough benefit to patients to justify its high cost, and did not qualify for special	01/03/2013	37
23 Jan 2013	TA271	Diabetic macular oedema - fluocinolone acetonide intravitreal implant	NICE does not recommend fluocinolone acetonide intravitreal implants for people with chronic diabetic macular oedema when other treatments have not worked well enough as they concluded they do not provide enough benefit to patients to justify their high cost.	01/03/2013	37

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
27 Feb 2013	TA275	Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban	NICE recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease - see guidance for eligibility criteria.	10/05/2013	72
27 Feb 2013	TA274	Macular oedema (diabetic) - ranibizumab	NICE recommends ranibizumab as a possible treatment for problems with sight due to diabetic macular oedema in some people - see guidance for eligibility criteria.	10/05/2013	72
27 Mar 2013	TA277	Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated	NICE is unable to recommend the use of this in the NHS because no evidence submission was received from the manufacturer of the technology.	10/05/2013	44
27 Mar 2013	TA276	Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin	NICE recommends tobramycin and colistimethate sodium dry powders for inhalation as possible treatments for chronic pseudomonas lung infection in some people with cystic fibrosis.	10/05/2013	44
24 Apr 2013	TA282	Idiopathic pulmonary fibrosis - pirfenidone	NICE recommends pirfenidone as a possible treatment for some people with idiopathic pulmonary fibrosis.	26/07/2013	93
24 Apr 2013	TA278	Asthma (severe, persistent, patients aged 6+, adults) - omalizumab	NICE recommends omalizumab as possible additional treatment to standard asthma therapy for some people aged 6 years and over with severe persistent allergic	26/07/2013	93
24 Apr 2013	TA279	Vertebral fractures - vertebroplasty and kyphoplasty	NICE recommends vertebroplasty and kyphoplasty (without stenting) as possible treatment options for some people with spinal compression fractures caused by osteoporosis.	10/07/2013	77

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
24 Apr 2013	TA281	Gout - canakinumab (terminated appraisal)	NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from the manufacturer of the technology.	26/07/2013	93
24 Apr 2013	TA280	Rheumatoid arthritis - abatacept (2nd line)	NICE recommends abatacept taken with methotrexate as a possible treatment option for some adults with rheumatoid arthritis.	26/07/2013	93
22 May 2013	TA284	Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)	NICE does not recommend bevacizumab, given with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).	26/07/2013	65
22 May 2013	TA283	Macular oedema (retinal vein occlusion) - ranibizumab (TA283)	NICE recommends ranibizumab as a possible treatment for some people who have sight problems because of macular oedema caused by retinal vein occlusion	26/07/2013	65
22 May 2013	TA285	Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285)	NICE does not recommend bevacizumab given with gemcitabine and carboplatin for treating adults with the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube or primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor	26/07/2013	65
22 May 2013	TA286	Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) (TA286)	NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer of the technology.	26/07/2013	65

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
26 Jun 2013	TA291	Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291)	NICE does not recommend pegloticase for people who have severe, chronic gout with tophi who have either tried oral gout drugs (specifically xanthine oxidase inhibitors) and still have high uric acid levels, or cannot take oral	13/09/2013	79
26 Jun 2013	TA287	Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban	NICE recommends rivaroxaban as a possible treatment for adults with pulmonary embolism and to prevent a further deep vein thrombosis or pulmonary embolism.	13/09/2013	79
26 Jun 2013	TA288	Type 2 diabetes - Dapagliflozin combination therapy (TA288)	NICE recommends dapagliflozin given with other drugs as a possible treatment for some people with type 2 diabetes.	13/09/2013	79
26 Jun 2013	TA289	Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289)	NICE does not recommend ruxolitinib for people with an enlarged spleen or symptoms from myelofibrosis.	13/09/2013	79
26 Jun 2013	TA290	Overactive bladder - mirabegron (TA290)	NICE recommends mirabegron as a possible treatment for the symptoms of overactive bladder in some people.	13/09/2013	79
24 Jul 2013	TA293	Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293) **Replaces TA205**	NICE recommends eltrombopag as a possible treatment for some adults with chronic immune (idiopathic) thrombocytopenic purpura	13/09/2013	51
24 Jul 2013	TA294	Aflibercept solution for injection for treating wet age related macular degeneration (TA294)	NICE recommends aflibercept injection as a possible treatment for some people with wet age-related macular degeneration	13/09/2013	51
24 Jul 2013	TA292	Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)	Aripiprazole is recommended as an option for treating moderate to severe manic episodes in adolescents with bipolar I disorder, within its marketing authorisation (that is, up to 12 weeks of treatment for moderate to severe manic episodes in bipolar I disorder in adolescents aged	13/09/2013	51

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
28 Aug 2013	TA295	Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)	NICE does not recommend everolimus, given with another drug called exemestane, for postmenopausal women with advanced breast cancer that is HER2 negative and hormone-receptor positive, and that has recurred or worsened after treatment with a non-steroidal aromatase inhibitor (another type of anticancer drug).	08/11/2013	72
25 Sep 2013	TA296	Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296)	NICE does not recommend crizotinib for people with a type of advanced non-small-cell lung cancer that is 'ALK-positive' and has been treated before.	08/11/2013	44
23 Oct 2013	TA297	Ocriplasmin for treating vitreomacular traction (TA297)	Ocriplasmin is recommended as a possible treatment for adults with an eye condition called vitreomacular traction who also have: <ul style="list-style-type: none"> • No epiretinal membrane (a thin layer of scar tissue over their retina, the light-sensitive area at the light-sensitive area at the back of the eye) and • A hole (up to 400 micrometers) in the centre of the retina Or <ul style="list-style-type: none"> • Severe sight problems 	08/11/2013	16
27 Nov 2013	TA298	Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)	Ranibizumab is recommended as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia. NICE recommends it is only be prescribed if the manufacturer makes it available to the NHS under terms agreed with the Department of Health as part of a patient access scheme.	10/01/2014	44
27 Nov 2013	TA299	Leukaemia (chronic myeloid) - bosutinib (TA299)	Bosutinib is not recommended for previously treated Philadelphia-chromosome-positive chronic myeloid leukaemia.	10/01/2014	44

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
27 Nov 2013	TA300	Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300)	Peginterferon alfa with ribavirin is recommended as a possible treatment for children and young people with chronic hepatitis C	10/01/2014	44
27 Nov 2013	TA301	Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)	Fluocinolone acetonide intravitreal implants are recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if: <ul style="list-style-type: none"> • the implant is used in the eye with the artificial lens and • their diabetic macular oedema has not got better with other treatments 	10/01/2014	44
27 Nov 2013	TA302	Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302)	NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer of the technology.	10/01/2014	44
22 Jan 2014	TA303	Multiple sclerosis (relapsing) - teriflunomide (TA303)	Teriflunomide is recommended as a possible treatment for adults with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis.	14/03/2014	51
26 Feb 2014	TA305	Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion	Aflibercept injections are recommended as a possible treatment for people with sight problems caused by macular oedema from central retinal vein occlusion.	14/03/2014	16
26 Feb 2014	TA306	Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B- cell lymphoma	Pixantrone monotherapy is recommended as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B- cell lymphoma if: <ul style="list-style-type: none"> •they have previously been treated with rituximab and •they are having third- or fourth-line treatment. 	14/03/2014	16

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
26 Feb 2014	TA304	Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (review of TA2 and TA44)	Prostheses for total hip replacement and resurfacing arthroplasty are recommended as treatment options for people with end-stage arthritis of the hip only if the prostheses have rates (or projected rates) of revision of 5% or less at 10 years.	20/05/2014	83
26 Mar 2014	TA307	Colorectal cancer (metastatic) - aflibercept	Aflibercept taken with FOLFIRI (a chemotherapy combination made up of 3 drugs) is not recommended for metastatic colorectal cancer that has got worse after taking chemotherapy that includes oxaliplatin.	09/05/2014	44
26 Mar 2014	TA308	Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)	Rituximab taken with glucocorticoids is recommended as a possible treatment for people with anti-neutrophil cytoplasmic antibody-associated vasculitis (that is, severely active granulomatosis with polyangiitis [also known as Wegener's granulomatosis] and microscopic polyangiitis) who meet particular eligibility criteria.	09/05/2014	44
23 Apr 2014	TA309	Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer	Pemetrexed is not recommended as maintenance treatment for people with locally advanced or metastatic non-squamous non-small-cell lung cancer after therapy with pemetrexed and cisplatin.	09/05/2014	16
23 Apr 2014	TA310	Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer	Afatinib is recommended as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if: <ul style="list-style-type: none"> •their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and •they have not had a type of drug called an EGFR-TK inhibitor before. 	09/05/2014	16

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
23 Apr 2014	TA311	Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell	Bortezomib (given with a drug called dexamethasone, or with dexamethasone and thalidomide) is recommended as a possible treatment for adults with multiple myeloma before having chemotherapy and stem cell transplantation, if their multiple myeloma has not been	09/05/2014	16
28 May 2014	TA312	Multiple sclerosis (relapsing-remitting) - alemtuzumab	Alemtuzumab is recommended as a possible treatment for people with active relapsing–remitting multiple sclerosis.	11/07/14	44
28 May 2014	TA313	Psoriatic arthritis (active) - ustekinumab	Ustekinumab (given by itself or with methotrexate) is not recommended for active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or DMARDs) has not worked well enough.	11/07/14	44
25 Jun 2014	TA314	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (Updates TA95 & TA120)	<ul style="list-style-type: none"> • Implantable cardioverter defibrillators are recommended as a possible treatment for people who have had a serious ventricular arrhythmia, who have an inherited heart condition linked to a high risk of sudden death, or who have had surgery to repair congenital heart disease. • Implantable cardioverter defibrillators, and cardiac resynchronisation therapy with defibrillation or pacing, are recommended as possible treatments for certain people with heart failure because of left ventricular dysfunction (see the guidance for more information). 	23/09/2014	90
25 Jun 2014	TA315	Canagliflozin in combination therapy for treating type 2 diabetes (TA315)	<ul style="list-style-type: none"> • If a person needs to take 2 antidiabetic drugs, canagliflozin is recommended as a possible treatment for people with type 2 diabetes when taken with a drug called metformin, only if the person: <ul style="list-style-type: none"> • cannot take a type of drug called a sulfonylurea or • is at significant risk of hypoglycaemia or its consequences. 	14/11/2014	142

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
			<ul style="list-style-type: none"> • If a person needs to take 3 antidiabetic drugs, canagliflozin is recommended as a possible treatment when taken with either metformin and a sulfonylurea, or metformin and a type of drug called a thiazolidinedione. • Canagliflozin is recommended as a possible treatment <p><i>NB whilst the formulary process for Canagliflozin in combination therapy for treating type 2 diabetes was completed, this treatment was available through the CHS pharmacy for patients who met these criteria.</i></p>		
30 Jul 2014	TA316	Enzalutamide for metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen	<p>Enzalutamide is recommended as a possible treatment option for adults with metastatic hormone-relapsed prostate cancer, who have already had treatment with docetaxel-containing chemotherapy.</p> <p><i>NB whilst the formulary process was completed, this treatment was available through the CHS pharmacy for patients who met these criteria.</i></p>	14/11/2014	107
30 Jul 2014	TA317	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182)	<p>Prasugrel 10 mg is recommended as a possible treatment for adults with acute coronary syndrome who are having percutaneous coronary intervention.</p> <p><i>NB whilst the formulary process was completed, this treatment was available through the CHS pharmacy for patients who met these criteria.</i></p>	14/11/2014	107

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee CPC	Time to Implementation (days)
30 Jul 2014	TA318	Lubiprostone for treating chronic idiopathic constipation	<p>Lubiprostone is recommended as an option for treating chronic idiopathic constipation for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered. If treatment with lubiprostone is not effective after 2 weeks, the person should be re-examined and the benefit of continuing treatment reconsidered.</p> <p><i>NB whilst the formulary process was completed, this treatment was available through the CHS pharmacy for patients who met these criteria.</i></p>	14/11/2014	107
30 Jul 2014	TA319	Ipilimumab for previously untreated advanced (unresectable or metastatic)	<p>Ipilimumab is recommended as a possible treatment for adults with advanced (unresectable or metastatic) melanoma that has not been treated before.</p> <p><i>NB whilst the formulary process was completed, this treatment was available through the CHS pharmacy for patients who met these criteria.</i></p>	14/11/2014	107
27 Aug 2014	TA320	Dimethyl fumarate for treating relapsing remitting multiple sclerosis	<p>Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis.</p>	14/11/2014	79
29 Oct 2014	TA321	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma	<p>Dabrafenib (also known as Tafinlar) is recommended as a possible treatment for people with melanoma that has spread, can't be removed by surgery and is BRAF V600 mutation-positive.</p>	14/11/2014	16

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
24 Sep 2014	TA322	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic	This drug is recommended as a possible treatment for people with these conditions when other treatments haven't worked well enough.	14/11/2014	51
26 Nov 2014	TA323	Erythropoiesis stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended as possible treatments for anaemia in people having chemotherapy to treat cancer.	16/01/2015	51
26 Nov 2014	TA324	Dual chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of TA88)	Dual-chamber pacemakers are recommended as a possible treatment for people with symptomatic bradycardia due to sick sinus syndrome without <i>NB whilst the formulary process is completed, this treatment is available for patients who met these criteria.</i>		Awaiting Implementation
26 Nov 2014	TA325	Nalmefene for reducing alcohol consumption in people with alcohol dependence	NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink. It is recommended as a possible treatment for people with alcohol dependence who: <ul style="list-style-type: none"> • are still drinking more than 7.5 units per day (for men) and more than 5 units per day (for women) 2 weeks after an initial assessment and • do not have physical withdrawal symptoms and • do not need to either stop drinking straight away or stop drinking completely. Nalmefene should only be taken if the person is also having ongoing support to change their behaviour.	16/01/2015	51
26 Nov 2014	TA326	Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE	Imatinib (Glivec) is recommended as a possible treatment for up to 3 years, for people who had gastrointestinal stromal tumours that were removed by surgery, when there is a high risk that the tumour may come back.	16/01/2015	51

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
17 Dec 2014	TA328	Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment because no evidence submission was received from Gilead Sciences .	16/01/2015	30
17 Dec 2014	TA327	Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary	Dabigatran etexilate (also known as Pradaxa) is recommended as a possible treatment for adults with deep vein thrombosis or pulmonary embolism.	16/01/2015	30
28 Jan 2015	HST1	Eculizumab for treating atypical haemolytic uraemic syndrome	Eculizumab is recommended for funding for treating atypical haemolytic uraemic syndrome, only if certain arrangements are in place.	17/03/2015	48
25 Feb 2015	TA329	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and	Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) are recommended as are possible treatments for adults with moderate to severe ulcerative colitis if conventional therapy hasn't worked or isn't suitable. Infliximab is also recommended as a possible treatment for children or young people aged 6–17 years with severe ulcerative colitis, if conventional therapy hasn't worked or	13/03/2015	16
25 Feb 2015	TA330	Sofosbuvir for treating chronic hepatitis C	Sofosbuvir (also known as Sovaldi) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. It is taken with other drugs (peginterferon alfa and ribavirin, or ribavirin alone).	13/03/2015	16
25 Feb 2015	TA331	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C	Simeprevir (also known as Olysio) with peginterferon alfa and ribavirin is recommended as a possible treatment for adults with genotype 1 or 4 chronic hepatitis C.	13/03/2015	16
25 Feb 2015	TA332	Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer	NICE does not recommend Sipuleucel-T as a treatment for people with metastatic non-visceral hormone-relapsed prostate cancer, who have few or no symptoms and when chemotherapy is not yet suitable.	13/03/2015	16

Date of Publication	Guidance Title of Guidance Number	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)	
25 Feb 2015	TA333	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	NICE recommends axitinib as a possible treatment for adults with advanced renal cell carcinoma when drugs called tyrosine kinase inhibitors or cytokines have not worked.	13/03/2015	16
25 Feb 2015	TA334	Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease because no evidence submission was received from Bayer.	13/03/2015	16
25 Mar 2015	TA335	Rivaroxaban for preventing adverse outcomes after acute management of acute coronary	Rivaroxaban (Xarelto) with aspirin alone, or with aspirin plus clopidogrel, is recommended as a possible treatment for adults who have had a certain type of heart problem (acute coronary syndrome with raised cardiac biomarkers). The aim is to prevent further problems, such as heart attack or stroke, caused by blood clots.	08/05/2015	44
25 Mar 2015	TA336	Empagliflozin in combination therapy for treating type 2 diabetes	<ul style="list-style-type: none"> • If a person needs to take 2 antidiabetic drugs, empagliflozin (Jardiance) is recommended as a treatment for type 2 diabetes when taken with metformin, only if the person cannot take a type of drug called a sulfonylurea or is at significant risk of hypoglycaemia or its consequences. • If a person needs to take 3 antidiabetic drugs, empagliflozin is recommended as a treatment for type 2 diabetes when taken with either metformin and a sulfonylurea, or with metformin and a type of drug called a thiazolidinedione. • Empagliflozin is also recommended as a treatment for type 2 diabetes when taken with insulin, with or without other antidiabetic drugs. 	08/05/2015	44
25 Mar 2015	TA338	Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib	Pomalidomide (Imnovid), given with dexamethasone, is not recommended for treating relapsed and refractory multiple myeloma in people whose disease has gotten worse despite having had both lenalidomide and bortezomib	08/05/2015	44

Date of Publication	Guidance Number	Title of Guidance	Summary of Recommendations	Ratified at Croydon Prescribing Committee (CPC)	Time to Implementation (days)
25 Mar 2015	TA337	Rifaximin for preventing episodes of overt hepatic encephalopathy	Rifaximin (Targaxan) is recommended for preventing episodes of hepatic encephalopathy in people aged 18 years or older.	08/05/2015	44
27 May 2015	TA340	Ustekinumab for treating active psoriatic arthritis	Ustekinumab (Stelara) is recommended as a possible treatment, alone or with methotrexate, for adults with active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or DMARDS) has not worked well enough if: <ul style="list-style-type: none"> • treatment with tumour necrosis factor (TNF) alpha inhibitors is not suitable for them, or • the person has had a TNF alpha inhibitor before 	03/07/2015	37
27 May 2015	TA341	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Apixaban (Eliquis) is recommended as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism.	03/07/2015	37
27 May 2015	TA342	Vedolizumab for treating moderately to severely active ulcerative colitis	Vedolizumab (Entyvio) is recommended as a possible treatment for adults with moderate to severe ulcerative colitis.	03/07/2015	37
27 May 2015	TA343	Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia	Obinutuzumab (Gazyvaro), given with chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if they have other conditions that make full-dose fludarabine unsuitable for them and bendamustine is not suitable for them.	03/07/2015	37
27 May 2015	TA339	Omalizumab for previously treated chronic spontaneous urticari	Omalizumab (Xolair) is recommended as a possible treatment for people aged 12 years and over with severe chronic spontaneous urticarial under certain circumstances.	03/07/2015	37